Philips Respironics to Discontinue U.S. CPAP Sales

Philips Respironics announced that it has agreed to the terms of a consent decree which will require it to cease the sale of new CPAP or BiPAP sleep therapy devices or other respiratory care devices in the U.S.

The consent decree, which is being finalized by the Department of Justice and will be submitted to the relevant U.S. court for approval, according to Philips, “will provide Philips Respironics with a roadmap of defined actions, milestones, and deliverables to demonstrate compliance with regulatory requirements and to restore the business.”

The decision comes after an analysis from the Pittsburgh Post-Gazette and ProPublica found that Philips withheld over 3,700 complaints about the machines from the FDA for more than 11 years. The beleaguered company has also seen several large recalls and issues for other products.

To read the whole story, click here to subscribe.

Related Topics